作者:Scott D. Kuduk、Christina N. Di Marco、Ronald K. Chang、William J. Ray、Lei Ma、Marion Wittmann、Matthew A. Seager、Kenneth A. Koeplinger、Charles D. Thompson、George D. Hartman、Mark T. Bilodeau
DOI:10.1016/j.bmcl.2010.02.096
日期:2010.4
The phenyl ring in a series of quinolone carboxylic acid M1 positive allosteric modulators was replaced with a variety of heterocycles in order to reduce protein plasma binding and enhance CNS exposure.
Bicyclic Aryl and Heteroaryl Sodium Channel Inhibitors
申请人:Amgen Inc.
公开号:US20130150339A1
公开(公告)日:2013-06-13
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.
The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
Bicyclic aryl and heteroaryl sodium channel inhibitors
申请人:Amgen Inc.
公开号:US09012443B2
公开(公告)日:2015-04-21
The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7.
The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.